Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer

被引：10
|
作者：
Liu, Yi-Fu [1 ]
Fu, Sheng-Qiang [1 ]
Yan, Yu-Chang [1 ]
Gong, Bin-Bin [1 ]
Xie, Wen-Jie [1 ]
Yang, Xiao-Rong [1 ]
Sun, Ting [1 ]
Ma, Ming [1 ]
机构：
[1] Nanchang Univ, Affiliated Hosp 1, Dept Urol, Nanchang 330000, Jiangxi, Peoples R China
来源：
DRUG DESIGN DEVELOPMENT AND THERAPY | 2021年 / 15卷
关键词：
gonadotropin-releasing hormone; prostate cancer; degarelix; relugolix; ANDROGEN-DEPRIVATION THERAPY; ANTIANDROGEN FLARE PROTECTION; URINARY-TRACT SYMPTOMS; III EXTENSION TRIAL; OF-LIFE IMPROVEMENT; OPEN-LABEL; GNRH ANTAGONIST; PHASE-II; JAPANESE PATIENTS; 1-ARM CROSSOVER;
D O I：
10.2147/DDDT.S291369
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Gonadotropin-releasing hormone (GnRH) receptor agonists are still the most commonly used androgen deprivation treatment (ADT) drugs for prostate cancer in clinical practice. Currently, the GnRH receptor antagonists used for endocrine therapy for prostate cancer primarily include degarelix and relugolix (TAK-385). The former is administered by subcutaneous injection, while the latter is an oral drug. Compared to GnRH agonists, GnRH antagonists reduce serum testosterone levels more rapidly without an initial testosterone surge or subsequent microsurges. This review focuses on the mechanism of action of GnRH antagonists and agonists, the developmental history of GnRH antagonists, and emerging data from clinical studies of the two antagonists used as endocrine therapy for prostate cancer.
引用
收藏
页码：639 / 649
页数：11
相关论文
共 50 条
  • [1] Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer
    Kittai, Adam S.
    Blank, Jessica
    Graff, Julie N.
    ONCOLOGY-NEW YORK, 2018, 32 (12): : 599 - 606
  • [2] Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer
    Moussa, Mohamad
    Papatsoris, Athanasios
    Dellis, Athanasios
    Abou Chakra, Mohamed
    Fragkoulis, Charalampos
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (17) : 2373 - 2381
  • [3] Gonadotropin-releasing hormone agonists in the treatment of prostate cancer
    Labrie, F
    Bélanger, A
    Luu-The, V
    Labrie, C
    Simard, J
    Cusan, L
    Gomez, J
    Candas, B
    ENDOCRINE REVIEWS, 2005, 26 (03) : 361 - 379
  • [4] The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer
    Cirne, Filipe
    Aghel, Nazanin
    Petropoulos, Jo-Anne
    Klotz, Laurence
    Lenihan, Daniel J.
    Saad, Fred
    Pinthus, Jehonathan
    Leong, Darryl P.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (03) : 253 - 262
  • [5] Gonadotropin-releasing hormone antagonists
    Herbst, KL
    CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (06) : 660 - 666
  • [6] Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer
    Van Poppel, Hendrik
    Abrahamsson, Per-Anders
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (10) : 830 - 837
  • [7] Gonadotropin-releasing hormone antagonists in the treatment of uterine leiomyoma
    Felberbaum, Ricardo E.
    Kuepker, Wolfgang
    Balogh, Balint
    Diedrich, Klaus
    GYNAKOLOGE, 2020, 53 (08): : 529 - 536
  • [8] Gonadotropin-releasing hormone/gonadotropin-releasing hormone receptor signaling in the placenta
    Sasaki, Kirsten
    Norwitz, Errol R.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2011, 18 (06) : 401 - 408
  • [9] Gonadotropin-releasing hormone receptor expression in the human prostate
    Tieva, Å
    Stattin, P
    Wikström, P
    Bergh, A
    Damber, JE
    PROSTATE, 2001, 47 (04): : 276 - 284
  • [10] Non-peptide gonadotropin-releasing hormone receptor antagonists
    Betz, Stephen F.
    Zhu, Yun-Fei
    Chen, Chen
    Struthers, R. Scott
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (12) : 3331 - 3348
12345